|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KLKB1 |
Gene summary for KLKB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KLKB1 | Gene ID | 3818 |
| Gene name | kallikrein B1 | |
| Gene Alias | KLK3 | |
| Cytomap | 4q35.2 | |
| Gene Type | protein-coding | GO ID | GO:0002254 | UniProtAcc | A8K9A9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3818 | KLKB1 | NAFLD1 | Human | Liver | NAFLD | 3.10e-06 | 7.87e-01 | -0.04 |
| 3818 | KLKB1 | S43 | Human | Liver | Cirrhotic | 1.15e-06 | -1.24e-01 | -0.0187 |
| 3818 | KLKB1 | HCC1_Meng | Human | Liver | HCC | 4.53e-29 | -1.51e-01 | 0.0246 |
| 3818 | KLKB1 | HCC2_Meng | Human | Liver | HCC | 1.61e-05 | -1.83e-01 | 0.0107 |
| 3818 | KLKB1 | HCC2 | Human | Liver | HCC | 5.34e-19 | 4.00e+00 | 0.5341 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00610417 | Liver | NAFLD | regulation of wound healing | 39/1882 | 134/18723 | 5.52e-10 | 1.28e-07 | 39 |
| GO:00420607 | Liver | NAFLD | wound healing | 84/1882 | 422/18723 | 6.56e-10 | 1.37e-07 | 84 |
| GO:0042730 | Liver | NAFLD | fibrinolysis | 15/1882 | 25/18723 | 1.26e-09 | 2.30e-07 | 15 |
| GO:0030195 | Liver | NAFLD | negative regulation of blood coagulation | 21/1882 | 49/18723 | 2.42e-09 | 4.05e-07 | 21 |
| GO:1900047 | Liver | NAFLD | negative regulation of hemostasis | 21/1882 | 50/18723 | 3.78e-09 | 5.40e-07 | 21 |
| GO:0030193 | Liver | NAFLD | regulation of blood coagulation | 24/1882 | 66/18723 | 9.30e-09 | 1.26e-06 | 24 |
| GO:0050819 | Liver | NAFLD | negative regulation of coagulation | 21/1882 | 53/18723 | 1.33e-08 | 1.69e-06 | 21 |
| GO:1900046 | Liver | NAFLD | regulation of hemostasis | 24/1882 | 68/18723 | 1.84e-08 | 2.09e-06 | 24 |
| GO:0061045 | Liver | NAFLD | negative regulation of wound healing | 26/1882 | 78/18723 | 1.86e-08 | 2.09e-06 | 26 |
| GO:19030347 | Liver | NAFLD | regulation of response to wounding | 41/1882 | 167/18723 | 4.70e-08 | 4.58e-06 | 41 |
| GO:0050818 | Liver | NAFLD | regulation of coagulation | 24/1882 | 71/18723 | 4.80e-08 | 4.60e-06 | 24 |
| GO:0051917 | Liver | NAFLD | regulation of fibrinolysis | 10/1882 | 14/18723 | 7.05e-08 | 6.34e-06 | 10 |
| GO:00075994 | Liver | NAFLD | hemostasis | 49/1882 | 222/18723 | 9.23e-08 | 7.59e-06 | 49 |
| GO:00075964 | Liver | NAFLD | blood coagulation | 48/1882 | 217/18723 | 1.16e-07 | 8.81e-06 | 48 |
| GO:00508174 | Liver | NAFLD | coagulation | 48/1882 | 222/18723 | 2.40e-07 | 1.61e-05 | 48 |
| GO:0031639 | Liver | NAFLD | plasminogen activation | 12/1882 | 24/18723 | 8.76e-07 | 4.60e-05 | 12 |
| GO:1903035 | Liver | NAFLD | negative regulation of response to wounding | 26/1882 | 94/18723 | 1.18e-06 | 5.66e-05 | 26 |
| GO:0072376 | Liver | NAFLD | protein activation cascade | 8/1882 | 12/18723 | 3.51e-06 | 1.40e-04 | 8 |
| GO:00458627 | Liver | NAFLD | positive regulation of proteolysis | 65/1882 | 372/18723 | 6.58e-06 | 2.29e-04 | 65 |
| GO:0002526 | Liver | NAFLD | acute inflammatory response | 26/1882 | 112/18723 | 3.68e-05 | 9.23e-04 | 26 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
| hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
| hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KLKB1 | SNV | Missense_Mutation | rs755781116 | c.553G>A | p.Val185Met | p.V185M | P03952 | protein_coding | deleterious(0) | possibly_damaging(0.493) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | |
| KLKB1 | SNV | Missense_Mutation | novel | c.1033T>C | p.Cys345Arg | p.C345R | P03952 | protein_coding | tolerated(0.17) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KLKB1 | SNV | Missense_Mutation | rs763038724 | c.230N>T | p.Cys77Phe | p.C77F | P03952 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| KLKB1 | SNV | Missense_Mutation | rs201643294 | c.682C>T | p.Arg228Trp | p.R228W | P03952 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-BH-A1EW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| KLKB1 | insertion | Frame_Shift_Ins | novel | c.408_409insACTGATG | p.Cys137ThrfsTer10 | p.C137Tfs*10 | P03952 | protein_coding | TCGA-A8-A09T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | ||
| KLKB1 | deletion | Frame_Shift_Del | novel | c.1607delN | p.Lys537ArgfsTer2 | p.K537Rfs*2 | P03952 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| KLKB1 | SNV | Missense_Mutation | c.70N>G | p.Gln24Glu | p.Q24E | P03952 | protein_coding | tolerated(0.41) | benign(0.041) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| KLKB1 | SNV | Missense_Mutation | c.353N>C | p.Gly118Ala | p.G118A | P03952 | protein_coding | deleterious(0) | benign(0.299) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KLKB1 | SNV | Missense_Mutation | rs144541812 | c.1486A>G | p.Thr496Ala | p.T496A | P03952 | protein_coding | deleterious(0) | possibly_damaging(0.567) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| KLKB1 | SNV | Missense_Mutation | rs146525902 | c.1772N>A | p.Arg591His | p.R591H | P03952 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3818 | KLKB1 | DRUGGABLE GENOME, PROTEASE, ENZYME | KVD001 | |||
| 3818 | KLKB1 | DRUGGABLE GENOME, PROTEASE, ENZYME | ANTITHROMBIN | |||
| 3818 | KLKB1 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 252166701 | ||
| 3818 | KLKB1 | DRUGGABLE GENOME, PROTEASE, ENZYME | antibody | 315661179 | LANADELUMAB | |
| 3818 | KLKB1 | DRUGGABLE GENOME, PROTEASE, ENZYME | Ecallantide | ECALLANTIDE | ||
| 3818 | KLKB1 | DRUGGABLE GENOME, PROTEASE, ENZYME | Lanadelumab | LANADELUMAB | ||
| 3818 | KLKB1 | DRUGGABLE GENOME, PROTEASE, ENZYME | BCX4161 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |